Vincerx Pharma (VINC) Revenue & Revenue Breakdown
Vincerx Pharma Revenue Highlights
Vincerx Pharma Revenue by Period
Vincerx Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Vincerx Pharma generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Vincerx Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.31M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $127.00K | -109.07% |
| 2020-12-31 | $-1.40M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | - |
Vincerx Pharma generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Vincerx Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| APLT | Applied Therapeutics | $9.99M | $190.00K |
| FRTX | Fresh Tracks Therapeutics | $8.01M | - |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| LVTX | LAVA Therapeutics | $6.77M | $6.99M |
| XOMA | XOMA | $4.76M | $11.09M |
| SNTI | Senti Biosciences | $2.56M | - |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| VCNX | Vaccinex | $570.00K | $232.00K |
| RZLT | Rezolute | - | - |
| GRCL | Gracell Bio | - | - |
| BCAB | BioAtla | - | - |
| TARA | Protara Therapeutics | - | - |
| PCSA | Processa Pharmaceuticals | - | - |
| NLTX | Neurogene | - | - |
| MNPR | Monopar Therapeutics | - | - |
| VINC | Vincerx Pharma | - | - |
| SIOX | Sio Gene Therapies | - | - |
| SRZN | Surrozen | - | - |
VINC Revenue FAQ
What is Vincerx Pharma’s yearly revenue?
Vincerx Pharma's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. VINC's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Vincerx Pharma’s quarterly revenue?
Vincerx Pharma's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). VINC's quarterly revenue for Q4 2023 was $1.31M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Vincerx Pharma’s revenue growth rate?
Vincerx Pharma's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.